Viridian Therapeutics
Viridian Therapeutics' revenue rose 23359.9% to $71 million in fiscal 2025. Its operating margin was −512.9%, up from −99,018.2% a year earlier. Free cash flow was −$277 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Viridian Therapeutics does
Viridian Therapeutics is a biotechnology company developing antibody medicines for autoimmune and rare diseases. It has no approved product and has never had revenue from product sales. Its main focus is thyroid eye disease (TED), a rare autoimmune condition that causes inflammation around the eye and can make the eyes bulge.
Its lead candidate, veligrotug, targets a protein called IGF-1R. The company sent a marketing application for it to the FDA in October 2025. The FDA accepted it for filing in December 2025, gave it Priority Review and set a target decision date of June 30, 2026. The company is also running a global phase 3 trial called STRIVE. It has candidates that block FcRn, a protein linked to several autoimmune disorders, and an inhibitor of TSHR for TED and Graves' disease.
The company says it is preparing to launch its first product, if approved. It is building sales, marketing, patient services and supply operations. It finds drugs through its own research and by licensing them from others, and it can make biologic medicines itself.
Its biggest risks, as it describes them
- Losses since it began and no revenue from product sales, so it may never be profitable.
- Needing more capital, which could dilute shareholders or force it to cut back programs.
- Clinical trials that are costly, slow and may fail to show safety and effectiveness.
- Regulatory approval that may be delayed or refused, and ongoing rules even after approval.
- Not being entitled to further milestone payments under the DRI Purchase and Sale Agreement.
Income statement
Viridian Therapeutics lost money in fiscal 2025: a net loss of $343 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 197 | 425 | 477 | 718 | 875 |
| Debt incl. finance leases | 0 | 5 | 20 | 21 | — |
| Net debt (negative means net cash) | −197 | −420 | −457 | −697 | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.1x | 0.0x | — |
| Interest coverage | −26,576.0x | −268.6x | −191.2x | −136.1x | −73.4x |
| Current ratio | 14.7x | 12.9x | 18.3x | 15.4x | 12.7x |
| Quick ratio | 14.7x | 12.9x | 18.3x | 15.4x | 12.7x |
Cash flow
Projections
Project Viridian Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $20.0 million of Viridian Therapeutics shares on the open market, and 1 insider sold $418,990.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Jennifer TousignantChief Legal Officer | Sold | 14,212 | $24.50 | $348,194 | Form 4 |
| May 11, 2026 | Fairmount Healthcare Fund II L.P.Director, 10% owner | Bought | 1,176,470 | $17.00 | $20.0 million | Form 4 |
| Dec 31, 2025 | Jennifer TousignantChief Legal Officer | Sold | 2,272 | $31.16 | $70,796 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | — | — |
| Rule of 40 | −59,021.1% | −77,099.9% | 22,969.1% |
| Altman Z'' | 7.43 | 8.99 | 2.72 |
| Accruals ratio | −11.6% | −6.1% | −8.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | — | — |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 3 of 8 | — | — |
Compare
Put Viridian Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics | FY25 | 23,359.9% | −512.9% | −390.8% | — | — | — | |
| Kura Oncology | FY25 | 25.2% | −449.9% | −104.8% | — | — | 3 | Compare |
| Nuvation Bio | FY25 | 699.0% | −338.7% | −288.4% | — | — | — | Compare |
| Eton Pharmaceuticals | FY25 | 104.9% | −1.1% | 12.8% | −1.9% | 1.4x | 4 | Compare |
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 4 | 4 | 8 | 4 | 1 | 3 | 2 | 0 | 0 | 71 |
| Revenue growth | −39.1% | 15.1% | 109.5% | −46.8% | −76.5% | 182.2% | −40.2% | −82.3% | −3.8% | 23,359.9% |
| Gross profit | 1 | — | — | — | — | — | — | — | — | — |
| Research and development | 14 | 20 | 30 | 35 | 28 | 57 | 101 | 160 | 238 | 339 |
| Operating income | −17 | −26 | −33 | −42 | −110 | −80 | −134 | −254 | −299 | −363 |
| Net income | −17 | −26 | −33 | −42 | −111 | −79 | −130 | −238 | −270 | −343 |
| Diluted EPS (US$) | −423.15 | −20.70 | −16.50 | −20.04 | −31.13 | −6.66 | −4.05 | −5.31 | — | — |
| Diluted shares (millions) | 0 | 1 | 2 | 2 | 4 | 12 | 32 | 45 | — | — |
| Cash flow | ||||||||||
| Cash from operations | −15 | −28 | −27 | −36 | −30 | −55 | −94 | −184 | −232 | −276 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Free cash flow | −15 | −28 | −27 | −36 | −30 | −55 | −95 | −185 | −233 | −277 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 2 | 4 | 4 | 4 | 14 | 20 | 67 | 42 | 44 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 22 | 47 | 62 | 27 | 128 | 197 | 425 | 477 | 718 | 875 |
| Debt incl. finance leases | 5 | 10 | 10 | 8 | 0 | 0 | 5 | 20 | 21 | — |
| Total assets | 25 | 52 | 66 | 30 | 131 | 204 | 435 | 490 | 742 | 899 |
| Total liabilities | 10 | 14 | 15 | 14 | 11 | 16 | 40 | 48 | 71 | 177 |
| Shareholders' equity | −62 | 38 | 51 | 16 | 120 | 188 | 395 | 442 | 672 | 722 |
| Margins and ratios | ||||||||||
| Gross margin | 26.7% | — | — | — | — | — | — | — | — | — |
| Operating margin | −488.6% | −662.8% | −394.5% | −941.0% | −10,512.4% | −2,690.8% | −7,579.2% | −81,035.0% | −99,018.2% | −512.9% |
| Net margin | −496.8% | −662.3% | −390.0% | −938.6% | −10,544.3% | −2,680.2% | −7,329.2% | −75,711.5% | −89,387.1% | −483.6% |
| Free cash flow margin | −431.6% | −709.8% | −325.4% | −810.1% | −2,840.1% | −1,853.5% | −5,340.6% | −58,938.8% | −77,096.0% | −390.8% |
| Rule of 40 (growth + FCF margin) | −470.6% | −694.7% | −215.9% | −856.9% | −2,916.6% | −1,671.3% | −5,380.8% | −59,021.1% | −77,099.9% | 22,969.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −72.8% | −124.8% | −163.1% | −51.6% | −44.6% | −56.8% | −48.5% | −49.2% |
| Return on assets | −91.7% | −68.7% | −55.1% | −86.9% | −137.1% | −47.4% | −40.7% | −51.4% | −43.8% | −41.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |